SEC Comment Letter 0000000000-24-010445 to Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc.
Date: Sept. 16, 2024 · CIK: 0000894158 · Accession: 0000000000-24-010445
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282024
Letter
September 16, 2024 Steven Shallcross Chief Executive Officer Theriva Biologics, Inc. 9605 Medical Center, Suite 270 Rockville, MD 20850 Re:Theriva Biologics, Inc. Registration Statement on Form S-1 Filed September 10, 2024 File No. 333-282024 Dear Steven Shallcross: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Leslie Marlow, Esq.
Show Raw Text
September 16, 2024
Steven Shallcross
Chief Executive Officer
Theriva Biologics, Inc.
9605 Medical Center, Suite 270
Rockville, MD 20850
Re:Theriva Biologics, Inc.
Registration Statement on Form S-1
Filed September 10, 2024
File No. 333-282024
Dear Steven Shallcross:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Leslie Marlow, Esq.